Salix Pharmaceuticals Ltd (SLXP)
Quote as of 4:00 PM ET 09/02/2010 (NASDAQ GS)
| Last: 39.63 |
Change: $0.53 |
Percent Change: 1.36 |
Volume: 556,062 |
Salix Pharmaceuticals, Ltd. (Salix) is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases, which are affecting the digestive tract. The Company?s products include XIFAXAN, MOVIPREP, OSMOPREP, VISICOL, APRISO, METOZOLV, AZASAN, ANUSOL-HC, PROCTOCORT cream, PEPCID, Oral Suspension DIURIL and COLAZAL. The Company?s products under development include Rifaximin, Crofelemer, Balsalazide disodium tablet and Budesonide foam.
Analyst Opinions
| |
Current |
1 Mo. |
3 Mo. |
| Strong Buy |
11.00 |
9.00 |
10.00 |
| Buy |
0.00 |
1.00 |
0.00 |
| Hold |
1.00 |
1.00 |
1.00 |
| Sell |
0.00 |
0.00 |
0.00 |
| Strong Sell |
0.00 |
0.00 |
0.00 |
|
|
Average Recommendation
| Current |
1.08 |
| 1 Mo. Ago |
1.14 |
| 3 Mo. Ago |
1.09 |
Recommendation Scale
| Strong Sell: 3.0 |
Hold: 2.0 |
Strong Buy: 1.0 |
|